Background: This review was conducted to determine the clinical benefit and potential harms of screening for type 2 diabetes mellitus (T2DM) in asymptomatic adults.
INTRODUCTION
In 2006-2007, there were an estimated 211,168 new cases of diabetes diagnosed in Canada, with the prevalence of diagnosed diabetes for the whole population at 6.2% [1, 2] In 2008-2009, the national prevalence of diagnosed diabetes rose to 6.8% [2] . As diabetes diagnosis is often delayed, 20-50% of people with type 2 diabetes mellitus (T2DM) present with complications at the time of diagnosis and experience mortality rates at least two times higher than those without diabetes [2] [3] [4] [5] . The 2005 Canadian Task Force recommendations suggest screening for T2DM in: a) adults with hypertension; and b) hyperlipidemia, to prevent cardiovascular events and death [6] . Similarly, the 2008 United States Preventive Services Task Force (USPSTF) recommendations suggest screening asymptomatic adults with treated or untreated blood pressure greater than 135/80 mm Hg [7] ( Table 1) . Additional guidelines from the World Health Organization [8] and the American Association of Diabetes [9] suggest screening for T2DM should be considered in those with risk factors for diabetes (e.g. hypertension, hyperlipidemia, related cardiovascular disease, obesity, history of GDM), commencing at the age of 45 years and repeated in 3 year intervals [9] .
A review was completed to update the 2005 Canadian Task Force on Preventive Health Care (CTFPHC) guidelines on screening for T2DM and the evidence review of the 2008 USPSTF [6, 7] . The goal of the review was to determine the clinical benefit of screening for T2DM using fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), or a glycated hemoglobin (A1C) in asymptomatic adults, 18 years of age or older, at high risk for diabetes complications; and to determine the harms associated with screening for T2DM using, FPG, OGTT, or A1C in the same population.
The USPSTF questions and analytic framework were used to guide this review [7] . The key questions for the review included:
1.
What is the evidence for the clinical benefit of screening for T2DM using fasting plasma glucose, oral glucose tolerance test, or A1C in asymptomatic adults 18 years of age or older at high risk for diabetes complications to improve intermediate and final health outcomes?
2.
What is the evidence for the harm of screening for T2DM using fasting plasma glucose, oral glucose tolerance test, or A1C in asymptomatic adults 18 years of age or older at high risk for diabetes complications?
For the evidence review, harm outcomes included depression and anxiety. Several contextual questions were added to the USPSTF framework and were in the full review. The contextual questions addressed issues relevant when considering screening adults forT2DM, such as patient values, risk factors to guide screening, benefits and harms to early treatment; and the effectiveness of risk factor tools or questionnaires to predict T2DM. The review also addressed the following contextual questions:
1.
What are the most effective (accurate and reliable), risk assessment tools or questionnaires to predictT2DM?
2.
What risk assessment tools or questionnaires to predict T2DM have been validated in Canada?
3.
What is the yield (accuracy, reliability, prevalence, and feasibility) of screening for T2DM with FBG, OGTT, and A1C in adult patients?
The objective of this review is to update the evidence related to Key Question 1 of the USPTFS review; specifically, what is the evidence for the clinical benefit of screening for T2DM in high risk, asymptomatic adults 18 years of age or older. This review will report on the evidence for the harms of screening, as well as the evidence for contextual questions [3] [4] [5] .
METHODS
The USPSTF searched MEDLINE ® and the Cochrane Library for relevant English language systematic reviews, randomized controlled trials and observational studies published between March 2001 and July 2007, related to diabetes screening, and potential adverse effects. Clinical Trials.gov was also searched for relevant trials. To update the CTFPHC, the USPSTF search strategy was implemented, and all searches were updated from 2007 to February 2012. EMBASE was not searched, as it was not searched in the original USPSTF review. Reference lists of key articles were also reviewed. A grey literature search was also completed to find relevant Canadian data.
Eligible studies were in English or French and included asymptomatic adults 18 years or older at average or high risk for T2DM complications. Study designs for effectiveness of screening included randomized controlled trials or systematic reviews and meta-analyses and observational studies with mortality, cardiovascular mortality and diabetesrelated complications as outcomes. For harms and costeffectiveness, various study designs and multiple data sources were included. Titles and abstracts were reviewed in duplicate by members of the synthesis team; full text inclusion, quality assessment and data extraction were done by two people who resolved disagreements through discussions. Data were abstracted by two people using a standard format; Individual study quality was assessed as well as overall level of evidence. Study quality was based on the risk of bias due to limitations in design, inconsistency of findings, indirectness, imprecision and publication bias. The strength and quality of evidence was determined based on the GRADE system, using GRADEPro software [10] [11] [12] . We abstracted data about the patient population, the study design, analysis and results for each study. Reviews were quality assessed using the AMSTAR tool [13] .
The CTFPHC procedural manual allows for the use modeling studies when there is insufficient evidence to answer some or all of the key questions [14] . The Diabetes Screening Working Group determined that there was insufficient evidence to adequately answer components of the effectiveness question particularly regarding age cohorts, intervals and high risk groups requiring screening. A separate search for modeling studies and critical appraisal of the evidence followed the CTFPHC procedure manual and evidence-based tools [14, 15] . Briefly, the appraisal of modeling studies adopted a five-step process which involves assessment based on both applicability to the research question and study quality. The review process is described in detail in the full evidence review and synthesis report [16] .
RESULTS
Our search located 11,456 potentially relevant citations (Fig. 1) . Of these, title and abstract screening excluded 8,947; 2,340 papers were retrieved and assessed on inclusion criteria. Three studies met the criteria for the key questions: one new cohort study for mortality [17] ; and two studies for harm [18, 19] . For study characteristics, risk of bias and GRADE evidence related to mortality, please refer to Tables  2-4 ; for study characteristics, risk of bias and GRADE evidence related to harms, please refer to Tables 5-7 .
No new randomized controlled trials or systematic reviews were identified answering key question 1 since the 2008 USPSTF Recommendation Statement for the Screening of Type 2 Diabetes [20] . The 2008 USPSTF retrieved only three relevant studies (one case-control and two crosssectional studies) and found no benefit from screening for microvascular complications or any good data for the effectiveness of screening for T2DM in any targeted population [7] . Similarly to the 2008 USPSTF, two modeling studies were included for this updated review [21, 22] .
Screening for T2DM-Mortality
A population-based cohort study of 4,936 individuals examined the impact of early, delayed and no screening for T2DM using a 75 g OGTT and related cardiovascular (CV) risk factors on mortality [17] . All cause mortality was 21% lower in the cohort that participated in early screening versus not invited to screening (HR 0.79; 95% CI 0.63-1.00); similarly mortality was lower in those with delayed screening (HR 0.52; 95% CI 0.35-0.78) than those not invited to screening [17] . A study summary, risk of bias and GRADE evidence are found in Tables 2-4 .
Screening for T2DM -Modeled Studies
The review identified two studies of high methodological quality [21, 22] . In a UK study, screening appeared to be cost effective for the 40-70 year age cohort and most effective for hypertensive and obese individuals, as the costs of screening were offset by lower future treatment costs [21] . In a US study, the strategy of screening the entire population > 30 years of age every three years was the optimal strategy, assuming a decision maker was willing to pay at least $12,961 per QALY [22] . However, if there were recognizable disutilties associated with labeling, the benefits of screening may be outweighed by potential harms the 30 to 45 year old age group. The major limitation of both studies was that they required assumptions relating to glucose control and treatment effectiveness in screened individuals rather than based on empirical data. (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , diabetes was included as the underlying cause on the death certificate. 6 The authors report potential selection bias: "despite random selection of participants into invitation groups, participants who were offered screening were older at baseline, lived in more deprived areas and included a smaller proportion of men." However, we did not downgrade this criterion since in the analysis the researchers adjusted for age, sex and deprivation. 7 Single study. 
Screening for T2DM -Harms
The previous 2008 USPSTF identified eight observational studies that included heterogeneous populations and outcomes for harm, or which no serious adverse effects were noted [7] . The updated search identified two randomized controlled trials completed in the United Kingdom which reported on the adverse effects of screening for T2DM at the primary care level [18, 19] . One study reported small but significant short term trends for negative self-reported health (p=0.047) and worry (p=0.001) [18] . A second pilot trial determined those invited for T2DM screening reported being more anxious than those not invited (p=0.015); and those diagnosed with diabetes were more anxious than those without T2DM (p=0.031) [19] . Both studies noted that screening for T2DM in the primary care setting is feasible, may be associated with higher levels of short-term anxiety, and had limited psychological impact [18, 19] . Study summaries, risk of bias and GRADE evidence are found in Tables 5-7 .
Screening Risk Assessment Tools and Questionnaires
The literature search identified a high quality systematic review that examined the most accurate and reliable risk assessment tools or questionnaires to predict T2DM ( Table  8 ) [23] . Two additional papers were found validating the FINnish Diabetes RIsk SCore tool (FINDRISC) [24, 25] . The review specified seven validated score tools or models to be appropriate for clinical or public health settings: 1) FINDRISC; 2) Atherosclerosis Risk in Communities (ARIC); 3) Ausdrisk (Australia); 4) Cambridge risk score; 5) Framingham Offspring Study; 6) San Antonio risk score; and 7) QD Score [23] . The area under the receiver operating characteristic curve (AUROC) in the seven recommended tools ranged from 0.74 to 0.85 for internal validations and from 0.72 to 0.84 in external validations. Six out of the seven recommended tools have been validated internally and externally; Ausdrisk has not been externally validated and FINDRISC has been validated in the most countries (Finland, Holland, Denmark, Sweden, UK, Australia) [23] . The review also found preliminary data demonstrating a 
No
In the ADDITION (Cambridge) trial practices were randomly allocated to screening or control arms. In this substudy on the psychological impact of screening it was not possible to randomly select practices for screening because it started later than the main trial and many practices had already finished screening. Furthermore, three of the 10 screening sites included in this sub-study had already started the screening process. Therefore, randomization was not deemed adequate for the sub-study.
Allocation concealment?
No The authors do not discuss concealment of allocation. There was no randomized selection of practices for this study within the screening sites in the main ADDITION trial.
Blinding? Unclear The authors do not discuss issues related to blinding. Blinding of practices and participants would not possible in this study. The authors do not discuss blinding of outcome assessors.
Incomplete outcome data addressed?
No There was loss to follow up among the invited to screening non-attenders. An analysis was done to assess the impact if these non-responders had similar outcome measures at baseline. Non-response rates were similar across the three main groups from the initial test to 3-6 months (roughly 7%).
Free of selective reporting?
Yes All outcomes of interest were reported on in the results.
Free of other bias? Yes
No other biases were observed.
Item Judgement Description (Park et al., 2008) [19]
Adequate sequence generation?
Yes
The investigators indicate they used SPSS (v.9.0.1) to individually randomize participants into invited and noninvited groups.
Allocation concealment?
Unclear
The authors do not discuss concealment of allocation.
Blinding? Unclear The authors do not discuss issues related to blinding.
Incomplete outcome data addressed?
Yes An available case analysis was performed. All data for participants who completed the questionnaires (intervention n=77, control n=168) were included in the analysis.
Free of other bias? Yes
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FINDRISC is a validated and effective method to identify risk ofT2DM, particularly in persons age 45-64. It considers important variables such as age; body mass index (BMI); waist circumference; physical activity; diet; antihypertensive medications; history of elevated glucose; and family history of diabetes ( Table 9 ) [28] . The optimal cut point for detecting unknown diabetes was a FINDRISC score of greater or equal 15, yielding a sensitivity of 81.1% and specificity of 59.8%. The AUROC curve for detecting unknown diabetes was 0.724 (95% CI: 0.699, 0.770) [27] .
Screening Risk Assessment Tools and QuestionnairesValid for Canada
An 'accepted for publication' paper was located discussing the initial validation of the CANRISK tool [29] . The CANRISK was adapted from FINDRISC to account for 1 Eborall et al used adjusted mean differences for age and comorbidity (use of antihypertensives) to compute absolute effect. 2 Questionnaires were sent 6 weeks after last contact, either test or invitation. 3 Unclear allocation concealment. 4 No information regarding blinding. 5 Quality rating is for a single study, thus imprecision and publication bias criteria were rated as "no" and "unlikely" 6 Questionnaires given to participants after initial test or non-attendance (screening group) and to a sub-group of controls; data for screening attenders included in analysis only if questionnaire completed/returned before results of test received. 7 A non-randomized sample of screening practices was used. 8 Large loss to follow up (for the 3-6 and 12-15 month follow-up period. the diverse ethnic composition of the Canadian population. It was studied in a cross-sectional study for the detection of diabetes and pre-diabetes. The variables added were ethnicity, sex, education and macrosomia ( Table 9) . Selected screening thresholds in the paper version are reported as; 21 slightly elevated, 29 moderate, 32 balanced, 33 high and 43 very high. The balanced score has a sensitivity of 70%, specificity of 67%, PPV of 35% and NPV of 90% (Table 10 ) [29] .
Screening for T2DM -Yield of Tests
One high quality review was found that examined the most accurate and reliable tests to diagnose T2DM to patient outcomes [30] . Their analysis concluded that an A1C of 6.5% had a Positive Predictive Value (PPV) of 15.9%, a Negative Predictive Value (PNV) of 97%, sensitivity of 7.9% and specificity of 97% for the 10 year incidence of diabetes related retinopathy [30] . Graded as moderate quality evidence, the report recommended that the A1C test could be used as a diagnostic test and 6.5% is recommended as the cut point for diagnosing diabetes [30] .
Considering the quality of this review, an additional review for evidence for the effective tests for diagnosing diabetes was completed, locating 12 papers that compared A1C with FPG for the detection of diabetes [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . However, only four papers provided information on sensitivity, specificity, PPV/NPV and AUROC measures of A1C > 6.5% detectingT2DM. Those studies report a range of sensitivity 24-56.9; specificity 98.4-99; PPV 50-84; PNV 96.6-98.8 and AUROC. 078-892 [33, 37, 39, 42] . Fig. (1) . Search results for key questions. 
INTERPRETATION
Since the publication of the 2005 CTFPHC and the 2008 USPSTF report for screening for T2DM recommendations, there has been one new cohort study publication to contribute to the discussion about the effectiveness of screening for T2DM [6, 7] . Notably, the previous USPSTF also identified only observational studies and no randomized controlled trials for the effectiveness of screening forT2DM.
The population-based study demonstrated that screening had a non-significant reduction on mortality; however, no new evidence was found regarding the effectiveness of screening for T2DM on intermediate outcomes, such as, incidence ofT2DM, differences in A1C levels, and frequency of diagnosis. Notably, the Anglo Danish-Dutch Study of Intensive Treatment in people with screen detected diabetes in primary care (ADDITION) study group focused screening in relatively a low prevalence population (~3%) and only the top quartile of the population at risk were asked to participate in the trial [43, 44] . Cost effectiveness studies varied in their conclusions, particularly due to differences in modeling techniques and in assumptions relating to screening methods, glucose control requirements and future treatment protocols. The harms associated with screening for T2DM were minimal, with little effect on anxiety levels, self-rated health status and quality of life. Risk assessment tools with internal and external validity can be effective at identifying individuals who are at high risk of being diagnosed with diabetes. Screening with tests A1C, FPG or OGTT provide similar diagnostic outcomes, however A1C is easiest to administer and is cost effective.
This review is not without limitations. The search was limited to only those databases searched in the USPSTF review; therefore EMBASE was excluded. We found no new trials that examined the effectiveness of screening forT2DM. The studies found for the harms (anxiety) of screening were too heterogeneous for a meta-analysis.
Finally, the CTFPHC recommendations that were generated from this review include the screening of individuals deemed to be at high risk (1/3 or 33% risk of developing T2DM in 10 years) and very high risk (1/2 or 50% risk of developing T2DM in 10 years), as determined with a validated risk calculator, such as the FINDRISC or CANRISK [45] . Specifically, for adults that were at high risk of diabetes, a recommendation to screen every 3-5 years with an A1C test was made and for adults at very high risk, a recommendation of screening annually with an A1C test was stated. Unlike the ADA that states screening should commence at a certain age (45 years) [9] , the CTFPHC recommendations relying on calculated risk for T2DM, which considers variables such as age, obesity, history of elevated glucose, history of hypertension, family history of diabetes, limited activity levels and fruit and vegetable intake [45] .
The effectiveness of a T2DM screening intervention has not been adequately tested to date in a randomized controlled trial, particularly in individuals at high risk for diabetes and its complications. Screening interventions may include the tests (questionnaire, blood test) or the process (stepwise approach versus an alternative approach). Further research is required to determine the effect of screening forT2DM, the best approach to screening (detection, minimizes harm and is cost effective) and the best treatment once prediabetes or T2DM is diagnosed. 
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